Skip to content

Pfizer PFE Intangible assets — net

Intangible assets — net at other companies

Amgen logo
AmgenAMGN
AbbVie logo
AbbVieABBV
Moderna logo
ModernaMRNA
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Viatris logo
ViatrisVTRS
Organon logo
OrganonOGN

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$137.01B+11.1%
Enterprise value$199.68B+9.2%
P/E11.3×
P/S2.2×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's intangible assets — net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's intangible assets — net?
Pfizer (PFE) reported intangible assets — net of $30.92B in Q1 2026.
How has Pfizer's intangible assets — net changed year-over-year?
Pfizer's intangible assets — net decreased by 10.7% year-over-year, from $34.62B to $30.92B.
What is the long-term trend for Pfizer's intangible assets — net?
Over 5 years (2020 to 2025), Pfizer's intangible assets — net has grown at a 5.7% compound annual growth rate (CAGR), from $23.9B to $31.51B.